Reuters Health Information (2004-09-27): Peginterferon alpha-2B associated with serious ophthalmic pathology
Peginterferon alpha-2B associated with serious ophthalmic pathology
Last Updated: 2004-09-27 15:05:08 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Compromised vision is
associated with peginterferon alpha-2B (peg-IFN) treatment in a
significant proportion of patients with hepatitis C virus (HCV)/HIV
coinfection, according to a report in the September 3rd edition of AIDS.
Optic neuropathy and retinopathies have previously been reported
during interferon therapy for chronic HCV infection, the authors
explain, but they have not been reported with peg-IFN or in
"At this time, treatment for HCV has more benefit than harm," Dr.
Shyam Kottilil from National Institutes of Health, Bethesda, Maryland,
told Reuters Health. "Severe life-threatening ophthalmologic adverse
events (e.g. color vision loss) are rare, even in our study. However,
the message we wanted to deliver with this paper was to be cautious of
these adverse events and ensure all patients receive proper
ophthalmologic follow up."
Dr. Kottilil and colleagues investigated the ophthalmic effects of
peg-IFN treatment in a prospective, open-label trial, in which 23
patients with normal baseline ophthalmologic evaluations were treated
with peg-IFN and ribavirin for HCV infection.
More than one-third (8/23, 35%) of the patients developed ophthalmologic pathology, the authors report.
Six patients developed cotton wool spots by the 12-week fundoscopic
examination. These spots waxed and waned while treatment continued, the
Two other patients developed cataracts by week 20 of therapy, the
researchers note, and 2 patients showed decreases in red-green color
vision. The cataracts persisted after discontinuation of therapy, but
the color vision returned to baseline (with continued therapy in 1
patient and after cessation of treatment in the other).
"Clinicians who are treating HCV among HIV co-infected patients
should be cautious of these visual side effects," Dr. Kottilil said.
"All patients undergoing treatment should undergo a baseline
comprehensive eye exam and then should get their eyes examined
periodically as long as they are receiving therapy. When there is
evidence of optic nerve dysfunction -- as seen with two of our patients
-- consider discontinuation of drugs."
"At least from our minimal experience, the effects were reversible after withdrawal of the offending agent," Dr. Kottilil said.
"We have ongoing studies using combination therapy to treat HCV/HIV
co-infected patients at the NIH," Kottilil said. "We have designed a
very close ophthalmologic follow up to study any visual changes
associated with this treatment. Even though it is likely that
interferon is responsible for this adverse event, we cannot be
definitive about the causality unless we obtain more data from larger
cohorts of co-infected patients undergoing therapy."